<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169386</url>
  </required_header>
  <id_info>
    <org_study_id>AK102-101</org_study_id>
    <nct_id>NCT04169386</nct_id>
  </id_info>
  <brief_title>A Study of PCSK9 Inhibitor AK102 in Healthy Subjects</brief_title>
  <official_title>A First-in-Human,Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation,Phase 1 Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of AK102 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AD Pharmaceuticals Co., Ltd. (Guangzhou)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human,randomized, double-blind, placebo-controlled, single dose
      escalation, phase 1 study to evaluate the safety, tolerability, PK/PD and immunogenicity of
      AK102 administered subcutaneously in healthy subjects. Subjects will be randomized into 4
      planned single dose escalation cohorts or placebo cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent AE</measure>
    <time_frame>From single dose of AK102 through 12 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic characteristics of AK102</measure>
    <time_frame>over 12 weeks</time_frame>
    <description>Serum concentrations of AK102 at different timepoints before and after AK102 single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>At different time points from baseline through 12 weeks</time_frame>
    <description>Low-Density Lipoprotein Cholesterol (LDL-C) blood concentrations before and after AK102 single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in PCSK9</measure>
    <time_frame>At different time points from baseline through 12 weeks</time_frame>
    <description>PCSK9 blood concentrations before and after AK102 single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>At different time points from baseline through 12 weeks</time_frame>
    <description>The immunogenicity of AK102 will be assessed by summarizing the number of subjects who develop detectable ADAs.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>AK102 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK102 75mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK102 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK102 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK102 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK102 300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK102 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK102 500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK102</intervention_name>
    <description>AK102 single dose administered subcutaneously</description>
    <arm_group_label>AK102 150mg</arm_group_label>
    <arm_group_label>AK102 300mg</arm_group_label>
    <arm_group_label>AK102 500mg</arm_group_label>
    <arm_group_label>AK102 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo single dose administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent.

          -  No clinically significant abnormalities judged by the principal investigator based on
             the medical history, physical examination, electrocardiogram and routine laboratory
             evaluations.

          -  Low-density lipoprotein cholesterol (LDL-C) level of 70-190 mg/dL (inclusive).

          -  Body mass index (BMI) ≥18 and ≤ 28 kg/m^2 , body weight &gt;= 50 kg for male or &gt;= 45 kg
             for female.

        Exclusion Criteria:

          -  Triglyceride concentration &gt;400 mg/dL (4.5 mmol/L).

          -  History of hypersensitivity reactions to any substance of the investigation drug or
             other monoclonal antibodies.

          -  Drug or alcohol abuse within 6 months prior to dosing.

          -  Blood pressure &gt;140 mmHg (systolic) or &gt; 90 mmHg (diastolic)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Peking</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>November 17, 2019</last_update_submitted>
  <last_update_submitted_qc>November 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

